A mass balance study to determine the routes and rates of elimination of radioactivity, to determine total radioactivity in plasma and whole blood over time and compare levels to JTZ-951 and drug-derived entities in plasma and to determine pharmacokinetic (PK) parameters of JTZ-951 and its metabolite(s).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
6
Unnamed facility
Minneapolis, Minnesota, United States
Radioactivity concentration in urine, feces and dialysate
Time frame: maximum 20 days
Radioactivity concentration in whole blood and plasma
Time frame: maximum 20 days
Plasma concentrations of JTZ-951 and its metabolite
Time frame: maximum 20 days
Cmax (maximum concentration)
Time frame: maximum 20 days
tmax (time to reach maximum concentration)
Time frame: maximum 20 days
AUC (area under the concentration-time curve)
Time frame: maximum 20 days
t1/2 (elimination half-life)
Time frame: maximum 20 days
Number of adverse events
Time frame: maximum 20 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.